Skip to main content
NGeneBio Co., Ltd. logo

NGeneBio Co., Ltd. — Investor Relations & Filings

Ticker · 354200 ISIN · KR7354200008 KO Professional, scientific and technical activities
Open in API
Filings indexed 346 across all filing types
Latest filing 2026-03-31 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 354200

About NGeneBio Co., Ltd.

https://www.ngenebio.com/en/index.asp

NGeneBio Co., Ltd. is a precision diagnostics company specializing in Next-Generation Sequencing (NGS) technology. The company develops and commercializes molecular diagnostic products, including in-vitro diagnostic (IVD) and companion diagnostic (CDx) solutions. Its primary focus is on oncology, offering NGS panels for the analysis of solid tumors and hematologic malignancies. Complementing its diagnostic assays, NGeneBio provides integrated bioinformatics software for comprehensive data analysis and interpretation. The company's portfolio also includes liquid biopsy technologies and personal genetic testing services, all aimed at providing precise genomic information to guide clinical decision-making.

Recent filings

Filing Released Lang Actions
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 82% confidence The document is a statutory disclosure titled “주식매수선택권 부여에 관한 신고” (“Report on Grant of Stock Options”), submitted to the Financial Services Commission/Korea Exchange. It details the number of options granted, exercise price adjustments, grant conditions, and corrections to a prior submission. This is not an earnings announcement, management change, or general regulatory announcement; it specifically relates to the issuance of stock-based compensation (future share issuance). Therefore, it falls under Share Issue/Capital Change (Code: SHA).
2026-03-31 Korean
주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 75% confidence The document is a regulatory disclosure to the Korea Financial Services Commission/KRX regarding the grant of stock options (“주식매수선택권 부여”) by the company to its executives and employees. It is not an earnings release or annual report but a corporate action related to potential future issuance of new shares under option grants. This falls under the category for announcements of new share issues or capital changes. Therefore, the correct classification is Share Issue/Capital Change (SHA).
2026-03-31 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 92% confidence The document is the official report of the resolutions and voting outcomes at a regular shareholders’ meeting (정기주주총회). It lists agenda items, vote counts, approval status, and detailed director election results, which matches a Declaration of Voting Results. Thus, it falls under the ‘DVA’ category for shareholder vote results.
2026-03-31 Korean
사업보고서 (2025.12)
Audit Report / Information Classification · 93% confidence The document is titled “감사보고서” (Audit Report) and contains the independent auditor’s opinion, key audit matters, auditor’s responsibilities, review of internal control, and the accompanying audited financial statements for the fiscal year ending December 31, 2025. It is a standalone audit report rather than a full annual report or earnings release. Therefore, it fits the definition of an Audit Report / Information (Code: AR). FY 2025
2026-03-23 Korean
감사보고서제출
Audit Report / Information Classification · 95% confidence The document is a submission of an audit report (“감사보고서 제출”) including the auditor’s opinion, financial statement summaries for current and prior years, auditor name, report receipt date, and detailed audit-related disclosures. It is a standalone audit report rather than a full annual report or an announcement of publication. Thus it fits the Audit Report / Information category (AR). FY 2025
2026-03-23 Korean
주주총회소집공고
AGM Information Classification · 95% confidence The document is a 'Notice of General Meeting of Shareholders' (주주총회소집공고) for NGeneBio. It contains the meeting agenda, date, location, and detailed management information including board activities, director remuneration, and business overview. This type of document is a standard proxy statement/notice sent to shareholders to inform them of the upcoming AGM and provide necessary background information for voting. In the context of the provided categories, this fits the 'Proxy Solicitation & Information Statement' (PSI) classification.
2026-03-13 Korean

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.